Information Provided By: 
Fly News Breaks for March 26, 2019
CNAT
Mar 26, 2019 | 08:40 EDT
As previously reported, Roth Capital analyst Yasmeen Rahimi downgraded Conatus to Neutral from Buy, with a $1.70 price target after the company reported it did not meet primary endpoint in its ENCORE-NF trial, a 72-week study in 318 F1-F3 patients. Given that this follows failures of POLTHCV and ENCORE-PH, the analyst sees a lower probability of success of emricasan in the upcoming readouts of ENCORE-LF and extension phase of ENCOREPH, especially given the disease severity in these trials.
News For CNAT From the Last 2 Days
There are no results for your query CNAT
